Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies

Published:2016-08-01 Issue:2 Volume:11 Page:77-87
ISSN:1574-8847
Container-title:Current Clinical Pharmacology
language:en
Short-container-title:CCP

Author:

Casaluce Francesca,Sgambato Assunta,Sacco Paola,Palazzolo Giovanni,Maione Paolo,Rossi Antonio,Ciardiello Fortunato,Gridelli Cesare

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy;Medicine in Drug Discovery;2024-09

2. Natural product-derived ALK inhibitors for treating ALK-driven lung cancers: an in silico study;Molecular Diversity;2024-08-08

3. Non-small Cell Lung Cancer Treatment: Current Status of Drug Repurposing and Nanoparticle-based Drug Delivery Systems;Turkish Journal of Biology;2024-04-26

4. A new approach used in docking study for predicting the combination drug efficacy in EML4-ALK target of NSCLC;Journal of Biomolecular Structure and Dynamics;2022-07-13

5. EML4‑ALK fusion gene in non‑small cell lung cancer (Review);Oncology Letters;2022-06-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP